L-ornithine L-aspartate in Overt Hepatic Encephalopathy
L-ornithine L-aspartate in Overt Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a potentially reversible functional disorder of the brain with
 neurological and psychiatric symptoms. HE occurs in up to 70% of patients with cirrhosis at
 some time during the course of disease. The chief neurotoxin implicated in the development of
 HE is ammonia. An important aim of treatment of HE is the reduction of the ammonia in the
 body by lowering the amount of ammonia produced and increasing its detoxification. Enteric
 production of ammonia can be decreased by non-absorbable disaccharides such as lactulose and
 antibiotics such as rifaximin. L-ornithine- L-aspartate (LOLA), the salt of the natural amino
 acids ornithine and aspartate acts through the mechanism of substrate activation to detoxify
 ammonia. In clinical trials, LOLA has shown a statistically significant effect with respect
 to reduction in HE grade, reduction of blood ammonia concentration and positive effects on
 psychomotor function in patients of cirrhosis with minimal HE and overt chronic Grade I HE,
 as compared to placebo. However, there is lack of data on the efficacy of LOLA in patients
 with overt acute hepatic encephalopathy which is one of the major causes of hospital
 admissions and resource utilization in decompensated cirrhotics. Each admission for HE causes
 a major financial loss to the family and financial burden on the society. Any drug which
 decreases the hospital stay by rapidly improving HE, will clearly lead to decreased hospital
 costs to the individual and the society as a whole. Hence, such a trial is a national
 priority. The investigators hypothesize that LOLA, if added to the standard treatment of
 overt acute HE (i.e lactulose), may lead to a faster recovery and decrease in hospital stay
 of these patients. In this prospective, randomized, placebo controlled trial, the
 investigators aim to evaluate the efficacy of intravenous L-ornithine, L-aspartate in
 reversal of overt acute hepatic encephalopathy in patients with liver cirrhosis.
A. Introduction and Review of literature

 Hepatic encephalopathy (HE) is broadly defined as an alteration in mental status and
 cognitive function occurring in presence of liver failure. The clinical picture of HE arises
 as a complication of chronic and, more rarely, acute liver disease. HE occurs in up to 70% of
 patients with cirrhosis at some time during the course of their disease (1,2). It is
 characterized by personality changes, intellectual impairment and a depressed level of
 consciousness. HE may be clinical unapparent (minimal HE) detected by abnormal
 neuropsychometric or neurophysiological tests (3). The common presentation is overt HE which
 occurs in patients with advanced cirrhosis with portal-systemic collateral circulation.
 Episodes of HE in patients with cirrhosis are induced by precipitating factors, like
 dehydration, hypokalemia, large protein intake, gastrointestinal bleeding, constipation,
 infections, use of psychotropic drugs, alcohol intake or acute liver injury (hepatitis).

 Pathogenesis of hepatic encephalopathy In patients with liver cirrhosis, increasing
 structural replacement of hepatocytes with connective tissue leads to the loss of functioning
 hepatic parenchymal tissue and a reduction in the detoxification capacity of the liver. In
 addition, developing portal hypertension leads to the formation of a collateral circulation
 through which non-detoxified blood can by-pass the liver to reach the systemic circulation.
 Both these mechanisms contribute to the neurotoxins present in portal vein blood reaching the
 brain via the systemic circulation. A number of neurotoxins have been implicated in the
 pathogenesis of HE with ammonia being the most important (4,5). Fundamental conceptual
 advances in our understanding of hepatic encephalopathy have confirmed the central role of
 ammonia in the pathogenesis of portosystemic encephalopathy. Ammonia disrupts the function of
 neurones and astrocytes, giving rise to the symptoms of hepatic encephalopathy.

 Classification/Grading of HE can be classified as type A (in Acute Liver Failure), B (in
 Portosystemic shunts without intrinsic liver disease) and C (patients of cirrhosis with
 portal hypertension/or portosystemic shunts) (5,6). In cirrhotics, the type C HE is further
 classified into Episodic, Persistent and Minimal HE. Chronic persistent overt HE patients are
 those who can be relatively stable with little day to day fluctuation in their mental status.
 Episodic (Unstable) HE patients are defined as those who were previously stable, but who over
 hours and possibly days develop clinically discernible features of HE, requiring medical
 attention and hospitalization. Minimal HE is clinically inapparent and detected by abnormal
 neuropsychometric or neurophysiological tests (3).

 A precise gradation of HE is essential to prognosticate and plan an appropriate approach to
 treatment. According to the severity, HE has been traditionally divided into four stages
 based on alterations in the state of consciousness, intellectual function, behaviour, and
 neuromuscular signs (West Haven scale) (5).

 A new classification has been recently proposed called the SONIC classification (7). This was
 necessary because the differentiation between minimal and Grade I HE is not reliable, but
 there is good inter-rater reproducibility in the identification of Grade II HE. It was
 suggested that patients with minimal HE and Grade I HE should be grouped together. It
 stresses that worsening cognitive function is continuum rather than categorical as emphasized
 in the Vienna 11th World Congress. It classifies patients with cirrhosis as being unimpaired
 and impaired neurocognitive function. Impaired cognitive function is subdivided into Covert
 HE (Minimal HE and Grade I HE) and Overt HE (Grades II-IV). It is thus inclusive of the West
 Haven criteria, yet emphasizes continuity as opposed to being categorical. The neurocognitive
 function of impaired, unstable patients can fluctuate from acute confusional syndrome to coma
 (Grades I to IV). They are the so called Type C- episodic HE patients.

 Therapy of hepatic encephalopathy The main objective of therapy of HE is to (a) decrease
 intestinally derived toxins produced by excessive bacterial activity and decrease ammonia
 production or (b) increase ammonia detoxification (1,2,8,9).

 1. Decrease ammonia production:

 Enteric production of ammonia can be decreased by non-absorbable disaccharides such as
 lactulose or lactitol and non-absorbable antibiotics such as rifaximin.
 Lactulose/lactitol pass through the small bowel undigested. In the colon, bacteria
 degrade lactulose to various organic acids (e.g. lactic acid, acetic acid) with
 subsequent lowering of colonic pH. The mode of ammonia lowering may involve
 bacteriostatic effects, cathartic effects, or enhancement of conversion of ammonia to
 ammonium with excess hydrogen ion. Presumably ammonium is then excreted into the feces
 and eliminated (9, 10). Lactulose remains the main stay of therapy of overt HE, despite
 the paucity and inconsistency of clinical trials demonstrating its efficacy (11). The
 dosage should be adjusted to accomplish two to three soft bowel movements each day.
 Lactulose can be given through a nasogastric tube or through retention enemas. The usual
 dose is 30-120 ml each day in divided doses. Stool pH should be below six. Side effects
 include bloating and flatulence. Severe diarrhea with dehydration and hyperglycemia and
 acidosis occurs if the dosage is too high.

 Non absorbable antibiotics neomycin, metronidazole, and paromomycin are traditional
 antibiotics for the treatment of HE (12). Due to ototoxic and nephrotoxic side effects,
 neomycin is now used infrequently. Metronidazole does not cause much side effects but
 therapy should not extend beyond two weeks to avoid neuropathy. More recently rifaximin
 has demonstrated to be as good as lactulose (13) or lactitol (14, 15) for patients with
 hepatic encephalopathy.

 2. Increase ammonia detoxification:

 Levels of ammonia can be decreased by detoxification. L-ornithine- L-aspartate (LOLA), the
 salt of the natural amino acids ornithine and aspartate acts through the mechanism of
 substrate activation to detoxify ammonia. Detailed mechanism of action and clinical trials on
 LOLA are discussed below.

 L-ornithine- L-aspartate (LOLA):

 L-ornithine- L-aspartate (LOLA) is the salt of the natural amino acids ornithine and
 aspartate.

 1. Mechanism of action:

 LOLA stimulates the urea cycle (which metabolizes ammonia to urea) in the liver (16,17).
 In the periportal hepatocytes that synthesize urea, ornithine serves as an activator of
 ornithine transcarbamoylase and carbamoyl phosphate synthetase. In addition, ornithine
 can acts as a substrate for urea genesis. Hence, LOLA can activate the periportal urea
 cycle in the liver. Aspartate and ornithine, after conversion to alpha- ketoglutarate,
 also serves as carbon sources for perivenous glutamine synthesis. In the skeletal
 muscle, LOLA upregulates glutamine synthesis by substrate provision for glutamine
 synthetase, although decreased muscle mass in cirrhosis does not allow this synthesis to
 be significant. Ammonia is consumed during urea formation and glutamine synthesis, and
 thereby LOLA decreases blood ammonia levels. Urea and glutamine (after further
 metabolism) can be excreted via the kidneys. LOLA thus activates the two important
 metabolic pathways in the human body for the detoxification of ammonia. In cirrhosis,
 there is some remaining liver cell mass that retains capacity to detoxify ammonia as
 opposed to acute liver failure.

 2. Trials of LOLA in Hepatic encephalopathy:

 LOLA has been used for many years for the treatment of HE in cirrhosis of the liver,
 especially minimal and overt chronic low grade HE. The clinical efficacy of LOLA has
 already been comprehensively investigated and reported in therapeutic observations,
 clinical trials (16, 18-25) and meta-analysis (26,27). In these studies, the use of LOLA
 as infusion, oral administration or a combination of the two, was documented in patients
 with mild to severe liver insufficiency. LOLA showed a statistically significant effect
 with respect to an improvement in mental state (reduction in the HE grade), increased
 detoxification (reduction of the ammonia concentration in the blood) and positive
 effects on psychomotor function (reduction of time required in the number connection
 test) in Minimal Hepatic Encephalopathy and overt chronic Grade I-II Hepatic
 Encephalopathy, and acute overt HE. With these findings, evidence-based medicine
 criteria for demonstrating efficacy have been fulfilled.

 In a recent randomized placebo controlled study conducted at Karachi (25), patients with
 acute HE were randomized to receive LOLA or placebo. NCT-A, ammonia level, clinical
 grade of HE and duration of hospitalization were assessed. Improvement in HE was higher
 (n=40, 66.7%) in LOLA group (n=28, 46.7%, p=0.027). Duration of hospitalization was
 lower in LOLA group compared to placebo (p=0.025). No side effects were observed in
 either group.

 3. Adverse effects of LOLA L-ornithine- L-aspartate is usually well tolerated (18-25). No
 serious adverse events have been reported so far in clinical trials. The various adverse
 events reported in about 14% patients treated with LOLA include:

 1. Nausea

 2. Vomiting

 3. Fatigue

 B. Materials and Methods

 1. Study design and setting:

 This will be a prospective, randomized, double blind, placebo controlled interventional
 study.

 The study will be conducted on patients of cirrhosis admitted with overt HE in the
 Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana and
 Department of Hepatology, GB Pant Hospital, New Delhi. Informed consent shall be taken
 from the nearest relative of the patient for enrollment in the trial.

 The study shall be presented for approval to the Institutional Ethics Committee prior to
 the enrollment of patients into the study. It shall be registered with Clinical Trial
 Registry, India and the ClinicalTrials.gov registry.

 2. Study population:

 Inclusion and exclusion criteria have been mentioned elsewhere.

 3. Study Methods:

 Assignment: Consecutive patients diagnosed to have acute overt HE will be randomized
 into two groups (group A and B) using sealed opaque envelopes containing
 computer-generated random numbers. There shall be no restriction, blocking or
 stratification of the randomization sequence. The research coordinator who will generate
 the sequence shall have no role in recruitment, treatment, or assessment of patients.

 Masking: Sequentially numbered boxes containing identical LOLA or placebo ampoules,
 according to the allocation sequence will ensure allocation concealment. The numbering
 of the boxes will be done by research coordinator, and concealed from the treating
 consultants. All study personnel will be blinded to the treatment assignment (placebo or
 LOLA) for the duration of the study. Placebo and LOLA will be similar in appearance and
 in the mode of administration. The code of the allocation sequence will remain with the
 research coordinator. It will be revealed only after the recruitment, data collection
 and analysis of results has been carried out. The coordinator will not have any access
 to the patients involved in the study.

 Randomization implementation: Enrollment of patients, assessing eligibility and
 obtaining informed consent will be carried out by one of the investigators (S.S. Sidhu
 or O. Goyal, BC Sharma) Study Intervention: The patients will be randomized to receive
 either placebo or LOLA at dose of 30 grams daily, by intravenous infusion over 24 hours.
 (The study drugs and placebo will be provided by Win Medicare Pvt Ltd., 1400, Modi
 tower, 98, Nehru Place, New Delhi- 110019). LOLA will be supplied as ampoules (each
 ampoule containing 5 grams LOLA in 10 ml clear solution). Six ampoules (i.e 30 g of
 LOLA) will be infused over 24 hours. The placebo vials (10 ml sterile water in each
 vial) will be identically supplied and infused. The dose of LOLA (30 g in 24 hours) was
 based on previous studies, showing the efficacy of this dose in decreasing ammonia
 levels (17,26,28). Both groups shall receive treatment for 5 days. Patients in both the
 groups who continue to have hepatic encephalopathy at the end of study period (5 days),
 will receive standard of care treatment, and would be counseled about liver transplant.

 4. Laboratory tests:

 Biochemical tests: Hemogram, blood glucose, liver function tests, prothrombin time,
 serum electrolytes, blood urea and serum creatinine will be done at baseline, and at 2nd
 and 5th day of treatment, or earlier if indicated. Serum AFP will be done at admission.
 Serum cytokine levels (Interleukin 1, 6, 10 and TNF-alpha) levels will be done at
 baseline and after 5 days of treatment.

 Microbiologic tests: A diagnostic paracentesis will be done in all patients with
 ascites, at baseline, to diagnose Spontaneous Bacterial Peritonitis. A repeat cell count
 (Total and differential) shall be done on day 5 with patients diagnosed to have
 Spontaneous Bacterial Peritonitis. Blood culture, urine culture, cultures of aspirates
 from endotracheal tubes in ventilated patients for aerobic and anerobic bacteria, and
 fungi shall be done. A chest radiograph shall also be done.

 Ammonia estimation: Fasting venous ammonia levels will be estimated by using the blood
 ammonia meter (PocketChem BA) at baseline and then daily for the next 5 days. The
 PocketChem BA ammonia meter is an apparatus for quick bedside blood ammonia estimation.
 It has been shown to have acceptable precision, adequate linearity, and satisfactory
 agreement with a enzymatic reference method commonly used in clinical laboratories (29).

 Measurement Principle: The PocketChem BA measures blood ammonia based on the
 micro-diffusion method. When the blood sample (20 microlitre) is applied to the
 sample-receiving layer of the test area on the test strip, the alkaline buffer agent
 (borate buffer) impregnated in the layer dissolves making the specimen alkaline. The
 ammonium ions in the specimen are gasified by the alkaline state into ammonia gas. The
 ammonia gas passes through the pores of the spacer to the indicator (bromocresol green)
 triggering color development. As the degree of color development is proportional to the
 concentration of ammonia gas produced, the blood ammonia level is quantitatively
 determined by measuring the color.

 Tests for etiologic evaluation: Etiology of cirrhosis will be taken as alcohol if there
 is a history of significant alcohol intake (40-60gm/day for females, and 60-80 gm/day
 for males for 10 years). Each patient will be tested for Hepatitis B surface antigen
 (HbsAg) and Anti-hepatitis C (HCV) antibody using a third generation commercial ELISA.
 Wherever indicated, autoimmune hepatitis will be diagnosed using antinuclear antibody,
 anti-smooth muscle antibody and anti-LKM; and hemochromatosis using serum iron, TIBC,
 ferritin and transferrin saturation. Each patient shall have an abdominal
 ultrasonography. UGI endoscopy would be done, if indicated.

 5. Standard of Care Treatment:

 Standard of care treatment for patients with cirrhosis and overt acute encephalopathy
 shall be given to all patients.

 1. Identification of other potential causes for altered mental state i.e. head injury
 or drug intoxication shall be done.

 2. Identification and treatment of the precipitating causes of encephalopathy such as
 sepsis, gastrointestinal bleeding, hypokalemia (serum Potassium < 3.5mEq/L),
 alkalosis, azotemia, dehydration, diuretics, constipation, large protein intake and
 psychoactive drugs shall be done.

 3. Lactulose syrup: 30-120 ml in three divided doses through a nasogastric tube/
 orally to produce 2-3 semi formed stools and/or lactulose retention enemas (300 ml
 lactulose +700 ml water) twice daily. No other ammonia lowering agent shall be
 given to these patients.

 6. Monitoring and follow-up:

 Clinical Monitoring:

 All patients will be admitted to the intensive care unit/ high dependency unit, and
 shifted to ward once they revert back to grade I HE. Continuous monitoring of vital
 signs shall be done. Neurologic monitoring shall be done twice daily and grading of
 mental state will be as per the West Haven Criteria.

 Definition of Response to therapy:

 The assessment of the clinical response will be defined as follows:

 1. Resolution: disappearance of the HE clinical syndrome during the study

 2. Improvement: a decrease in the HE by 1 grade, but not reaching grade 0

 3. No Improvement: no improvement in HE

 4. Failure: shift to a higher grade of HE.

 Biochemical monitoring:

 Biochemical monitoring and monitoring of ammonia levels shall be done as mentioned above
 (under 'laboratory tests')

 Monitoring for Adverse Events:

 Any adverse event will be recorded specifying the time of onset, the duration, the
 severity and the relationship to the test medication.

 Tolerability: Tolerability of the study drug will be assessed by comparison of full
 blood cell count, liver function tests and renal function tests at baseline and at end
 of treatment.

 7. End points:

 Primary end-point

 1. Completion of 5 days of treatment

 Secondary end-point

 1. Liver related death

 2. Death due to other causes

 3. Discontinuation due to adverse effects

 4. Discharge from hospital

 8. Sample size: Sample size for this study was estimated using results of a previous study
 which reported complete recovery of encephalopathy in 79% patients in LOLA group and
 55.6% patients in the placebo group (25). At 80% power and a 5% significance level
 (two-sided), 71 patients in each group would be required to detect a 22% difference in
 proportions. Assuming a dropout rate of 15% approximately (28), we will need to enroll
 164 patients, i.e. 82 in each treatment arm.

 9. Statistical Analysis: A chi-squared test will be used to compare the proportion of
 patients with complete reversal of HE after 5 days in LOLA treatment and placebo groups.
 A 95% confidence interval for the difference in proportions will also be calculated. A
 Chi-squared test will then be used to compare the HE grading at 5 days between the
 groups. Blood ammonia levels will be compared between groups using an independent
 samples t-test; while length of hospital stay is not expected to be normally distributed
 and therefore will be compared using a non-parametric Mann-Whitney test. All statistical
 tests will be 2-sided and using a 5% significance level.
Inclusion Criteria:

 -  Hepatic cirrhosis based on clinical, biochemical, radiological and/or histological
 data

 -  Patients with overt acute grade 2, 3 and 4 HE, according to the West Haven criteria,
 with or without precipitating factors.

 -  Age of patient 18-70 years

 Exclusion Criteria:

 -  Patients who are terminally ill

 -  Acute on chronic liver failure

 -  Hepatocellular carcinoma

 -  Wilson's disease as the etiological factor of liver disease

 -  Advanced cardiac or pulmonary disease

 -  Presence of underlying chronic renal failure

 -  Neuro-degenerative disease or major psychiatric illness

 -  Patients on sedatives or antidepressants

 -  Pregnancy or breastfeeding